PURPOSE: To investigate the associations of serum amyloid A (SAA) protein and soluble tumor necrosis factor receptors 1 and 2 (sTNF-R1 and sTNF-R2) with diabetic retinopathy (DR) in Hispanics. DESIGN: Prospective, nonrandomized, cross-sectional, family-based observational cohort study. PARTICIPANTS: A total of 473 Hispanic type II diabetic subjects in families ascertained via proband with DR. METHODS: Levels of SAA, sTNF-R1, and sTNF-R2 were measured with enzyme-linked immunosorbent assay. Diabetic retinopathy was assessed by fundus photography and graded using modified Airlie House classification. MAIN OUTCOME MEASURES: Levels of SAA, sTNF-R1, and sTNF-R2 to severity of DR with and without covariates. RESULTS: A direct association of sTNF-R1 (2.37±0.13, 2.15±0.09, 3.09±0.24, 3.25±0.46, 5.02±0.61 ng/ml; P < 0.0001) and sTNF-R2 (6.04±0.20, 6.25±0.52, 7.96±0.70, 8.14±1.13, 14.83±1.68 ng/ml; P < 0.0001) was found for no DR, mild nonproliferative DR (NPDR), moderate NPDR, severe NPDR, and proliferative DR, respectively. These associations remained significant after adjusting for age, gender, body mass index, glycosylated hemoglobin, diabetes duration, systolic blood pressure, and serum creatinine (P < 0.0001 for sTNF-R1 and P=0.0004 for sTNF-R2). A similar pattern was observed when we adjusted for urinary albumin:creatinine ratio in place of serum creatinine (P=0.005 for sTNF-R1 and P=0.02 for sTNF-R2). CONCLUSIONS: Levels of sTNF-R1 and sTNF-R2 are highly correlated with the severity of DR, suggesting that inflammation and insulin resistance may play a critical role in the development of DR. These may be useful biomarkers for DR, aiding in etiologic studies and possibly identifying at-risk patients for active intervention.
PURPOSE: To investigate the associations of serum amyloid A (SAA) protein and soluble tumor necrosis factor receptors 1 and 2 (sTNF-R1 and sTNF-R2) with diabetic retinopathy (DR) in Hispanics. DESIGN: Prospective, nonrandomized, cross-sectional, family-based observational cohort study. PARTICIPANTS: A total of 473 Hispanic type II diabetic subjects in families ascertained via proband with DR. METHODS: Levels of SAA, sTNF-R1, and sTNF-R2 were measured with enzyme-linked immunosorbent assay. Diabetic retinopathy was assessed by fundus photography and graded using modified Airlie House classification. MAIN OUTCOME MEASURES: Levels of SAA, sTNF-R1, and sTNF-R2 to severity of DR with and without covariates. RESULTS: A direct association of sTNF-R1 (2.37±0.13, 2.15±0.09, 3.09±0.24, 3.25±0.46, 5.02±0.61 ng/ml; P < 0.0001) and sTNF-R2 (6.04±0.20, 6.25±0.52, 7.96±0.70, 8.14±1.13, 14.83±1.68 ng/ml; P < 0.0001) was found for no DR, mild nonproliferative DR (NPDR), moderate NPDR, severe NPDR, and proliferative DR, respectively. These associations remained significant after adjusting for age, gender, body mass index, glycosylated hemoglobin, diabetes duration, systolic blood pressure, and serum creatinine (P < 0.0001 for sTNF-R1 and P=0.0004 for sTNF-R2). A similar pattern was observed when we adjusted for urinary albumin:creatinine ratio in place of serum creatinine (P=0.005 for sTNF-R1 and P=0.02 for sTNF-R2). CONCLUSIONS: Levels of sTNF-R1 and sTNF-R2 are highly correlated with the severity of DR, suggesting that inflammation and insulin resistance may play a critical role in the development of DR. These may be useful biomarkers for DR, aiding in etiologic studies and possibly identifying at-risk patients for active intervention.
Authors: Hussein A Rajab; Nathaniel L Baker; Kelly J Hunt; Richard Klein; Patricia A Cleary; John Lachin; Gabriel Virella; Maria F Lopes-Virella Journal: J Diabetes Complications Date: 2014-08-20 Impact factor: 2.852
Authors: Jane Z Kuo; Xiuqing Guo; Ronald Klein; Barbara E Klein; Pauline Genter; Kathryn Roll; Yang Hai; Mark O Goodarzi; Jerome I Rotter; Yii-Der Ida Chen; Eli Ipp Journal: J Clin Endocrinol Metab Date: 2015-05-28 Impact factor: 5.958
Authors: Kathryn A Bailey; Michael C Wu; William O Ward; Lisa Smeester; Julia E Rager; Gonzalo García-Vargas; Luz-Maria Del Razo; Zuzana Drobná; Miroslav Stýblo; Rebecca C Fry Journal: J Biochem Mol Toxicol Date: 2013-01-11 Impact factor: 3.642
Authors: Wayne H-H Sheu; Jane Z Kuo; I-Te Lee; Yi-Jen Hung; Wen-Jane Lee; Hin-Yeung Tsai; J-S Wang; Mark O Goodarzi; Ronald Klein; Barbara E K Klein; Eli Ipp; Shin-Yi Lin; Xiuqing Guo; Chang-Hsun Hsieh; Kent D Taylor; Chia-Po Fu; Jerome I Rotter; Yii-Der I Chen Journal: Hum Mol Genet Date: 2013-04-04 Impact factor: 6.150
Authors: Alicia J Jenkins; Mugdha V Joglekar; Anandwardhan A Hardikar; Anthony C Keech; David N O'Neal; Andrzej S Januszewski Journal: Rev Diabet Stud Date: 2015-08-10
Authors: Lucia Sobrin; Gayatri Susarla; Lynn Stanwyck; John M Rouhana; Ashley Li; Samuela Pollack; Robert P Igo; Richard A Jensen; Xiaohui Li; Maggie C Y Ng; Albert V Smith; Jane Z Kuo; Kent D Taylor; Barry I Freedman; Donald W Bowden; Alan Penman; Ching J Chen; Jamie E Craig; Sharon G Adler; Emily Y Chew; Mary Frances Cotch; Brian Yaspan; Paul Mitchell; Jie Jin Wang; Barbara E K Klein; Tien Y Wong; Jerome I Rotter; Kathyrn P Burdon; Sudha K Iyengar; Ayellet V Segrè Journal: Am J Ophthalmol Date: 2021-06-21 Impact factor: 5.488